Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Clinics Pub Date : 2025-01-01 DOI:10.1016/j.clinsp.2025.100602

Antonio Carlos Queiroz de Aquino , Ayane Cristine Alves Sarmento , Raphaell Lucas de Araújo Teixeira , Tâmilly Nascimento Batista , Cijara Leonice de Freitas , José Manuel Pérez Mármol , Lucia Alves Silva Lara , Ana Katherine Gonçalves

{"title":"Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials","authors":"Antonio Carlos Queiroz de Aquino , Ayane Cristine Alves Sarmento , Raphaell Lucas de Araújo Teixeira , Tâmilly Nascimento Batista , Cijara Leonice de Freitas , José Manuel Pérez Mármol , Lucia Alves Silva Lara , Ana Katherine Gonçalves","doi":"10.1016/j.clinsp.2025.100602","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Antidepressant-Induced Sexual Dysfunction (AISD) is a significant public health concern, and pharmacological treatments may offer potential solutions for managing this side effect. This study aims to assess the efficacy of these therapies in treating AISD in women, as well as their impact on improving depressive symptoms.</div></div><div><h3>Methods</h3><div>The authors conducted a search of PubMed, Cochrane, Scopus, Web of Science, Embase, and ClinicalTrials.gov databases up to July 3, 2024, including Randomized Controlled Trials (RCTs) comparing pharmacological treatments with placebo. The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2.0). Data synthesis was performed with RevMan 5.4, and the certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.</div></div><div><h3>Results</h3><div>Eleven studies, with 859 women, were included in the review. Two studies were used in the meta-analysis. The participants' ages ranged from 28 to 48 years. The interventions studied included <em>Aphrodite</em>, bupropion SR, ephedrine, <em>maca root, rosa damascena, saffron</em>, sildenafil, testosterone, and the compound VML-670. Bupropion SR 150 mg/b.i.d. showed improvements in three sexual function domains: desire (1.74 [1.03, 2.44], p = 0.00001), arousal (1.30 [1.16, 1.43], p = 0.00001), and orgasm (1.90 [1.78, 2.02], p = 0.00001) compared to placebo. However, it did not improve depressive symptoms (0.46 [-0.71, 1.63], p = 0.44). The GRADE rating for the evidence quality was low.</div></div><div><h3>Conclusions</h3><div>Bupropion SR 150 mg/b.i.d. is the most effective pharmacological treatment for AISD in women, though the evidence quality is low. Further clinical trials focusing on women with rigorous methodologies are needed to strengthen these findings.</div></div><div><h3>PROSPERO registration number</h3><div>CRD42024496931.</div></div>","PeriodicalId":10472,"journal":{"name":"Clinics","volume":"80 ","pages":"Article 100602"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1807593225000286","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Antidepressant-Induced Sexual Dysfunction (AISD) is a significant public health concern, and pharmacological treatments may offer potential solutions for managing this side effect. This study aims to assess the efficacy of these therapies in treating AISD in women, as well as their impact on improving depressive symptoms.

Methods

The authors conducted a search of PubMed, Cochrane, Scopus, Web of Science, Embase, and ClinicalTrials.gov databases up to July 3, 2024, including Randomized Controlled Trials (RCTs) comparing pharmacological treatments with placebo. The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2.0). Data synthesis was performed with RevMan 5.4, and the certainty of the evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.

Results

Eleven studies, with 859 women, were included in the review. Two studies were used in the meta-analysis. The participants' ages ranged from 28 to 48 years. The interventions studied included Aphrodite, bupropion SR, ephedrine, maca root, rosa damascena, saffron, sildenafil, testosterone, and the compound VML-670. Bupropion SR 150 mg/b.i.d. showed improvements in three sexual function domains: desire (1.74 [1.03, 2.44], p = 0.00001), arousal (1.30 [1.16, 1.43], p = 0.00001), and orgasm (1.90 [1.78, 2.02], p = 0.00001) compared to placebo. However, it did not improve depressive symptoms (0.46 [-0.71, 1.63], p = 0.44). The GRADE rating for the evidence quality was low.

Conclusions

Bupropion SR 150 mg/b.i.d. is the most effective pharmacological treatment for AISD in women, though the evidence quality is low. Further clinical trials focusing on women with rigorous methodologies are needed to strengthen these findings.

PROSPERO registration number

CRD42024496931.

查看原文本刊更多论文

抗抑郁药诱导的女性性功能障碍的药物治疗：随机临床试验的系统回顾和荟萃分析

背景：抗抑郁药引起的性功能障碍（AISD）是一个重要的公共卫生问题，药物治疗可能为控制这一副作用提供潜在的解决方案。本研究旨在评估这些疗法治疗女性AISD的疗效，以及它们对改善抑郁症状的影响。方法作者检索了截至2024年7月3日的PubMed、Cochrane、Scopus、Web of Science、Embase和ClinicalTrials.gov数据库，包括比较药物治疗与安慰剂治疗的随机对照试验（RCTs）。使用Cochrane风险偏倚工具（RoB 2.0）评估偏倚风险。使用RevMan 5.4进行数据合成，并使用分级推荐评估、发展和评价（GRADE）方法评估证据的确定性。结果：共有859名女性参与了7项研究。荟萃分析采用了两项研究。参与者的年龄从28岁到48岁不等。研究的干预措施包括阿芙罗狄忒、安非他酮SR、麻黄碱、玛卡根、大马士革玫瑰、藏红花、西地那非、睾酮和化合物VML-670。安非他酮SR 150mg /b.i d。与安慰剂相比，在三个性功能领域表现出改善：欲望（1.74 [1.03,2.44],p = 0.00001），性唤起（1.30 [1.16,1.43],p = 0.00001）和性高潮（1.90 [1.78,2.02],p = 0.00001）。然而，它并没有改善抑郁症状（0.46 [-0.71,1.63],p = 0.44）。证据质量的GRADE评分较低。结论安非他酮SR 150 mg/ bbid是女性AISD最有效的药物治疗方法，尽管证据质量较低。需要以严格的方法对妇女进行进一步的临床试验，以加强这些发现。普洛斯彼罗注册号crd42024496931。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinics 医学-医学：内科

CiteScore

4.10

自引率

3.70%

发文量

129

审稿时长

52 days

期刊介绍： CLINICS is an electronic journal that publishes peer-reviewed articles in continuous flow, of interest to clinicians and researchers in the medical sciences. CLINICS complies with the policies of funding agencies which request or require deposition of the published articles that they fund into publicly available databases. CLINICS supports the position of the International Committee of Medical Journal Editors (ICMJE) on trial registration.